Coya Therapeutics, Inc.
COYA
$4.48
-$0.07-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.64% | 197,900.00% | -- | -95.22% | 103.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.64% | 197,900.00% | -- | -95.22% | 103.39% |
| Cost of Revenue | -21.43% | 155.01% | 31.16% | -19.78% | 66.15% |
| Gross Profit | 27.48% | 49.34% | 129.11% | -206.73% | -64.59% |
| SG&A Expenses | 39.36% | 52.94% | 15.22% | 39.25% | 11.23% |
| Depreciation & Amortization | -58.82% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.67% | 101.30% | 23.16% | -1.25% | 42.08% |
| Operating Income | 0.61% | -4.34% | 56.93% | -98.22% | -40.65% |
| Income Before Tax | 1.37% | -56.91% | 47.39% | -110.78% | -44.63% |
| Income Tax Expenses | -- | 100.43% | -- | -- | -- |
| Earnings from Continuing Operations | 1.37% | -95.78% | 47.39% | -110.78% | -44.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.37% | -95.78% | 47.39% | -110.78% | -44.63% |
| EBIT | 0.61% | -4.34% | 56.93% | -98.22% | -40.65% |
| EBITDA | 0.56% | -4.34% | 57.01% | -98.42% | -40.70% |
| EPS Basic | 27.16% | -91.25% | 52.16% | -87.93% | -25.07% |
| Normalized Basic EPS | 27.28% | -5.69% | 63.78% | -87.95% | -25.68% |
| EPS Diluted | -46.06% | -91.25% | 52.16% | -87.93% | -25.07% |
| Normalized Diluted EPS | 27.28% | -5.69% | 63.78% | -87.95% | -25.68% |
| Average Basic Shares Outstanding | 35.43% | 2.36% | 9.93% | 12.13% | 15.65% |
| Average Diluted Shares Outstanding | 35.43% | 2.36% | 9.93% | 12.13% | 15.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |